Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 1/20 | 0.50 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.50 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.50 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.50 |
| ▸ | SYK | P43405 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | PPARD | Q03181 | 1/20 | 0.43 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31067871 | 0.86 | CYP4F2 (0.54) | KCNQ3KCNQ2KCNQ4KCNQ5SYK | |
| SCHEMBL25245034 | 0.86 | CYP4F2 (0.54) | KCNQ3KCNQ2KCNQ4KCNQ5SYK | |
| SCHEMBL28093133 | 0.85 | LMNA (0.49) | KCNQ3KCNQ2KCNQ4KCNQ5SYK | |
| SCHEMBL3928478 | 0.83 | KCNQ3 (0.47) | KCNQ3KCNQ2KCNQ4KCNQ5SYK | |
| SCHEMBL13301958 | 0.82 | KCNQ3 (0.53) | KCNQ3KCNQ2KCNQ4KCNQ5SYK | |
| SCHEMBL17634090 | 0.82 | PPARD (0.43) | KCNQ3KCNQ2KCNQ4KCNQ5PPARD | |
| SCHEMBL16046715 | 0.80 | MAOB (0.74) | KCNQ3KCNQ2KCNQ4KCNQ5SYK | |
| SCHEMBL3963929 | 0.80 | TRPV4 (0.44) | KCNQ3KCNQ2KCNQ4KCNQ5MAOB | |
| SCHEMBL2503936 | 0.80 | CYP4Z1 (0.50) | MAOBCYP4Z1SMN1; SMN2LMNATSHR | |
| SCHEMBL25213650 | 0.79 | KCNQ3 (0.47) | KCNQ3KCNQ2KCNQ4KCNQ5PPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10364208-B2 | Oxidative coupling of aryl boron reagents with SP3-carbon nucleophiles, and ambient decarboxylative arylation of malonate half-esters via oxidative catalysis | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2019-07-30 | — | — | US | disclosed |
| US-20180186721-A1 | OXIDATIVE COUPLING OF ARYL BORON REAGENTS WITH SP3-CARBON NUCLEOPHILES, AND AMBIENT DECARBOXYLATIVE ARYLATION OF MALONATE HALF-ESTERS VIA OXIDATIVE CATALYSIS | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2018-07-05 | — | — | US | disclosed |
| US-9085572-B2 | 4-(pyridin-3-yl)-2(pyridin-2yl)-1,2-dihydro-3H-pyrazol-3-one derivatives as specific HIF-pyrolyl-4-hydroxylase inhibitors for treating cardiovascular and haematological diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-07-21 | — | — | US | disclosed |
| US-9085572-B2 | 4-(pyridin-3-yl)-2(pyridin-2yl)-1,2-dihydro-3H-pyrazol-3-one derivatives as specific HIF-pyrolyl-4-hydroxylase inhibitors for treating cardiovascular and haematological diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-07-21 | — | — | US | disclosed |
| US-9085572-B2 | 4-(pyridin-3-yl)-2(pyridin-2yl)-1,2-dihydro-3H-pyrazol-3-one derivatives as specific HIF-pyrolyl-4-hydroxylase inhibitors for treating cardiovascular and haematological diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-07-21 | — | — | US | disclosed |
| US-20120322772-A1 | SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-12-20 | — | — | US | disclosed |
| US-20120322772-A1 | SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-12-20 | — | — | US | disclosed |
| US-20120322772-A1 | SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-12-20 | — | — | US | disclosed |
| US-8252817-B2 | Dipyridyl-dihydropyrazolones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-08-28 | — | — | US | disclosed |
| US-8252817-B2 | Dipyridyl-dihydropyrazolones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-08-28 | — | — | US | disclosed |
| US-8252817-B2 | Dipyridyl-dihydropyrazolones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-08-28 | — | — | US | disclosed |
| US-20100035906-A1 | Dipyridyl-dihydropyrazolones and their use | BAYER HEALTHCARE AG (DE) | 2010-02-11 | — | — | US | disclosed |
| US-20100035906-A1 | Dipyridyl-dihydropyrazolones and their use | BAYER HEALTHCARE AG (DE) | 2010-02-11 | — | — | US | disclosed |
| US-20100035906-A1 | Dipyridyl-dihydropyrazolones and their use | BAYER HEALTHCARE AG (DE) | 2010-02-11 | — | — | US | disclosed |
| WO-2009100403-A1 | SUBSTITUTED ARYL PYRIMIDINONES | NEUROGEN CORPORATION (US) | 2009-08-13 | — | — | WO | disclosed |
| EP-1877396-B1 | 4-(PYRIDIN-3-YL)-2-(PYRIDIN-2-YL)-1,2-DIHYDRO-3H-PYRAZOL-3-ONE DERIVATIVES AS SPECIFIC HIF-PROLYL-4-HYDROXYLASE INHIBITORS FOR TREATING CARDIOVASCULAR AND HAEMATOLOGICAL DISEASES | BAYER HEALTHCARE AG (DE) | 2009-02-18 | — | — | EP | disclosed |
| WO-2006114213-A1 | 4-(PYRIDIN-3-YL)-2-(PYRIDIN-2-YL)-1,2-DIHYDRO-3H-PYRAZOL-3-ONE DERIVATIVES AS SPECIFIC HIF-PROLYL-4-HYDROXYLASE INHIBITORS FOR TREATING CARDIOVASCULAR AND HAEMATOLOGICAL DISEASES | BAYER HEALTHCARE AG (DE) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10364208-B2 | Oxidative coupling of aryl boron reagents with SP3-carbon nucleophiles, and ambient decarboxylative arylation of malonate half-esters via oxidative catalysis | SOD1, AOC3, CBR3 | KCNQ3 2879/4885KCNQ2 4058/4885KCNQ4 3283/4885 |
| US-20120322772-A1 | SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES | PPIP5K2, THPO, DPYD | KCNQ3 3026/4885KCNQ2 3149/4885KCNQ4 2504/4885 |
| US-20100035906-A1 | Dipyridyl-dihydropyrazolones and their use | DPP7, DPP4, QDPR | KCNQ3 3393/4885KCNQ2 3647/4885KCNQ4 3232/4885 |
| US-20180186721-A1 | OXIDATIVE COUPLING OF ARYL BORON REAGENTS WITH SP3-CARBON NUCLEOPHILES, AND AMBIENT DECARBOXYLATIVE ARYLATION OF MALONATE HALF-ESTERS VIA OXIDATIVE CATALYSIS | SOD1, AOC3, CBR3 | KCNQ3 2879/4885KCNQ2 4058/4885KCNQ4 3283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.